Overview
Romidepsin is a cyclic peptide-derived histone deacetylase (HDAC) inhibitor, first isolated from Chromobacterium violaceum. It gained FDA approval in 2009 for treating cutaneous T-cell lymphoma (CTCL) and later for peripheral T-cell lymphoma (PTCL). The drug works by blocking HDAC enzymes, leading to increased histone acetylation and altered gene expression in cancer cells. This mechanism induces cell cycle arrest and apoptosis, making it a targeted therapy for specific hematologic malignancies.
Physical and Chemical Properties
Romidepsin appears as a white to off-white crystalline powder with limited solubility in aqueous solutions but dissolves well in dimethyl sulfoxide (DMSO). It is sensitive to light, heat, and humidity, requiring stringent storage conditions. The compound’s molecular structure includes a disulfide bond critical for its pro-drug activation. Upon cellular uptake, glutathione reduces this bond to release the active thiol form, which chelates zinc ions in HDAC’s catalytic site.
Main Applications
Romidepsin is clinically used for relapsed or refractory CTCL and PTCL, demonstrating response rates of 25-34% in pivotal trials. It is administered intravenously under medical supervision, typically in 4-week cycles. Research explores its potential in other cancers (e.g., multiple myeloma) and combination therapies with immunomodulators. Off-label use requires rigorous evaluation due to its narrow therapeutic index and side-effect profile.
Safety and Storage
Romidepsin carries risks of myelosuppression, infections, and cardiac arrhythmias (e.g., QT prolongation). Pre-treatment ECG and electrolyte monitoring are mandatory. Healthcare workers must avoid direct contact using gloves and eye protection. Unopened vials require storage at -20°C, protected from light. Reconstituted solutions are stable for up to 8 hours at room temperature but should be used immediately for optimal efficacy.
B2B Procurement Guide
Buyers should prioritize suppliers with Good Manufacturing Practice (GMP) certification and batch-specific Certificates of Analysis (CoA). Key parameters include purity (>98%), endotoxin levels, and sterility for injectable formulations. Cold chain logistics are essential to maintain stability. Negotiate bulk pricing for clinical or research use, and confirm regulatory documentation (e.g., FDA/EMA approval status) for international shipments.